Data/hora: 06/06/2024 03:23:29

Provedor de dados: | 56
País: | Brazil
Título: | Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects
Autores: | Sposito,A.C.; Mansur,A.P.; Maranhão,R.C.; Rodrigues-Sobrinho,C.R.M.; Coelho,O.R.; Ramires,J.A.F.
Data: | 2001-02-01
Ano: | 2001
Palavras-chave: | Etofibrate; Niacin; Lipoprotein (a); Triglycerides; Cholesterol.
Resumo: | Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased. Etofibrate, but not niacin, reduced Lp(a) by 26% and low-density lipoprotein (LDL) cholesterol by 23%. The hybrid compound etofibrate produced a more effective reduction in plasma LDL cholesterol and Lp(a) levels than controlled-release niacin in type IIb dyslipidemic subjects.
Tipo: | Info:eu-repo/semantics/article
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000200004
Editor: | Associação Brasileira de Divulgação Científica
Relação: | 10.1590/S0100-879X2001000200004
Formato: | text/html
Fonte: | Brazilian Journal of Medical and Biological Research  v.34 n.2 2001
Fonte: | info:eu-repo/semantics/openAccess